DEFICIAL

PF-0459 US

## CERTIFICATE OF TRANSMISSION

I hereby cartify that this paper is being facsimile transmitted to the attention of Examiner T. Scheiner, Group Art Unit 1662. U.S. Patent and Trademark Office to Facsimile No. (703) 305-3704 on the date shown below.

FAX RECEIVED

GROUP 1600

#8 7. 6ray

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal et al.

Title:

Signature

**HUMAN SIGNAL-CONTAINING PROTEINS** 

Serial No.:

09/002,485

Filing Date:

December 31, 1997

Examiner:

T. Scheiner

Group Art Unit:

1642

Assistant Commissioner for Patents Washington, D.C. 20231

## RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 U.S.C. 121 AND ELECTION OF SPECIES

Sir:

This communication is in response to the Restriction Requirement mailed September 30, 1998, in the above-referenced application.

Claims 1-23 were originally filed. In response to the restriction requirement, Applicants elect the claims of Group II (claims 2-14, 22 and 23) with traverse. Applicants submit that the invention encompassed by the claims of Group II (drawn to polynucleotides, etc.) could be examined at the same time as the inventions encompassed by the claims of Groups I, III-V. For example, a search of the prior art to determine the novelty of the polynucleotides of the invention would provide information regarding the novelty of the encoded polypeptides and compositions thereof and corresponding antibodies. Accordingly, because the searches required to identify prior art relevant to all claims would substantially overlap, Applicants respectfully submit that examination of originally filed claims 1-23 would pose no undue burden. Thus, Applicants

#36913

SERIAL NO. 09/002,485

BEST AVAILABLE COPY

PF-0459 US

request reconsideration and withdrawal of the Restriction Requirement and examination of the claims in Groups I-V.

In the event that the Examiner determines that the Restriction Requirement should be maintained, Applicants hereby cancel claims 1, and 15-21 without prejudice to renewal as being contained within the non-elected groups. Applicants reserve the right to prosecute the non-elected claims in subsequent divisional applications.

Applicants elect species SEQ ID NO: 102 as the polynucleotide sequence and SEQ ID NO: 25 as the corresponding polypeptide sequence for examination as applied to the claims in Group II (claims 2-14, 22 and 23).

Applicants believe that no fee is required with this communication. However, should the United States Patent and Trademark Office determine that a fee is due, the Assistant Commissioner is hereby authorized to charge the required amount to Deposit Account No. 09-0108.

This form is enclosed in duplicate.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Karen J. Zeller Reg. No. 37,071

FAX RECEIVED

**GROUP 1600** 

#34913

3174 Porter Drive

Phone: (650) 855-0555 Fax: (650) 845-4166

Palo Alto, California 94304

2

SERIAL NO. 09/002,485

BEST AVAILABLE COPY